List view / Grid view
New research from Gladstone Institutes shows that chronic overactivation of dopamine-producing neurons can directly trigger their death, offering new insights into why these cells deteriorate in Parkinson’s disease which could lead to potential therapies to slow its progression.
In this first-in-human Alzheimer’s study, Wnt-activated autologous stem cells are delivered intracerebroventricularly (directly into the brain) to address neuronal loss, while also reducing amyloid and tau biomarkers and improving cognition. Early data from this regenerative approach could help early drug discovery teams shape target selection, biomarker development and trial design.
Researchers have found that mitochondrial dysfunction in the blood-brain barrier may drive neuropsychiatric disease in 22q11.2 deletion syndrome – and that a cholesterol drug could restore barrier function and ease symptoms.
Researchers identified hyperactivity in a specific brain region as a driver of autism-like behaviours in mice – and reversed these symptoms using drugs first designed to treat epilepsy.
A new study has shown that small pond worms, called planaria, respond to psychiatric drugs like rodents – offering a promising new way of studying mental health conditions such as schizophrenia and addiction.
Scientists have developed a new computational model that reveals how the striosomal compartment of the brain’s striatum influences decision-making – which could lead to improved therapies for psychiatric disorders.
Researchers have developed an easy-to-use method for measuring leg dystonia in children with cerebral palsy – allowing doctors to personalise treatments more effectively.
New preclinical research suggests that evenamide – a glutamate modulator – targets hippocampal hyperexcitability, potentially addressing positive, negative and cognitive symptoms of schizophrenia.
New research from Harvard Medical School shows that natural lithium deficiency in the brain may be a key early factor driving Alzheimer’s disease – which allow for the development of new approaches to preventing and reversing cognitive decline.
Stanford Medicine researchers have developed a targeted brain cell transplant that replaced most diseased microglia in mice with Sandhoff disease – extending their lifespan and reversing symptoms
Drug discovery company, TauGen, has filed a US patent application for a new series of drug candidates targeting endoplasmic reticulum (ER) stress – a key factor in secondary brain injury following traumatic brain injury (TBI).
Porosome Therapeutics have announced new advancements in Alzheimer’s treatment – presenting therapies that restore neuronal function, reduce Tau protein levels and reverse disease pathology in human brain organoids.
Johns Hopkins University scientists have engineered a new multi-region brain organoid that mimics early human brain development. The model offers a powerful new tool for studying disorders like autism, schizophrenia and Alzheimer’s disease.
Researchers at Mount Sinai have mapped how the 5-HT1A serotonin receptor controls brain signalling – finding a hidden lipid ‘co-pilot’ that could lead to the development of more targeted antidepressants.
Researchers have discovered that the protein intersectin plays a crucial role in organising synaptic vesicles – enabling direct communication essential for learning and memory.
